Literature DB >> 10348771

In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients.

D J Hoban1, G G Zhanel, J A Karlowsky.   

Abstract

Fluconazole-resistant Candida albicans and intrinsically fluconazole-resistant Candida species have been reported as bloodstream isolates. However, an association between the isolation of fluconazole-resistant Candida from the bloodstream and patient risk factors for fungemia has not been established. The purpose of this study was to determine the prevalence of fluconazole resistance in bloodstream isolates of Candida species and Cryptococcus neoformans collected from patients with neutropenia, one of the most important risk factors for fungemia. MICs of voriconazole, fluconazole, itraconazole, ketoconazole, amphotericin B, and flucytosine were determined by the National Committee for Clinical Laboratory Standards M27-A method (1997). Voriconazole, on a per-weight basis, was the most active azole tested. Fluconazole resistance (MIC >/= 64 microg/ml) was not identified in any of the C. albicans (n = 513), Candida parapsilosis (n = 78), Candida tropicalis (n = 62), or C. neoformans (n = 38) isolates tested.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10348771      PMCID: PMC89297          DOI: 10.1128/AAC.43.6.1463

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program.

Authors:  M A Pfaller; R N Jones; S A Messer; M B Edmond; R P Wenzel
Journal:  Diagn Microbiol Infect Dis       Date:  1998-05       Impact factor: 2.803

2.  In vitro activity of voriconazole against Candida species.

Authors:  C A Kauffman; L T Zarins
Journal:  Diagn Microbiol Infect Dis       Date:  1998-05       Impact factor: 2.803

3.  Invasive fungal infections in Canada from 1992 to 1994.

Authors:  L Nicolle; C Rotstein; A Bourgault; G St-Germain; G Garber
Journal:  Can J Infect Dis       Date:  1998-11

4.  In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.

Authors:  F Marco; M A Pfaller; S Messer; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

Review 5.  Candidemia in a Canadian tertiary care hospital from 1976 to 1996.

Authors:  J A Karlowsky; G G Zhanel; K A Klym; D J Hoban; A M Kabani
Journal:  Diagn Microbiol Infect Dis       Date:  1997-09       Impact factor: 2.803

6.  In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole.

Authors:  M A Pfaller; S A Messer; R J Hollis; R N Jones; G V Doern; M E Brandt; R A Hajjeh
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

  6 in total
  10 in total

Review 1.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

Review 2.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

3.  In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.

Authors:  M A Pfaller; S A Messer; L Boyken; H Huynh; R J Hollis; D J Diekema
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

4.  Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution.

Authors:  M A Pfaller; A Espinel-Ingroff; E Canton; M Castanheira; M Cuenca-Estrella; D J Diekema; A Fothergill; J Fuller; M Ghannoum; R N Jones; S R Lockhart; E Martin-Mazuelos; M S C Melhem; L Ostrosky-Zeichner; P Pappas; T Pelaez; J Peman; J Rex; M W Szeszs
Journal:  J Clin Microbiol       Date:  2012-03-29       Impact factor: 5.948

Review 5.  Newer antifungal agents.

Authors:  Walid Abuhammour; Eyassu Habte-Gaber
Journal:  Indian J Pediatr       Date:  2004-03       Impact factor: 1.967

6.  Comparison of two microdilution methods for testing susceptibility of Candida spp. to voriconazole.

Authors:  Maria José Linares; Guadalupe Charriel; Francisco Solís; Manuel Casal
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

7.  Efficacy of voriconazole in experimental Cryptococcus neoformans infection.

Authors:  Nikolaos Mavrogiorgos; Oscar Zaragoza; Arturo Casadevall; Joshua D Nosanchuk
Journal:  Mycopathologia       Date:  2006-08       Impact factor: 3.785

Review 8.  In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.

Authors:  A Espinel-Ingroff; K Boyle; D J Sheehan
Journal:  Mycopathologia       Date:  2001       Impact factor: 3.785

9.  Effects of voriconazole on Cryptococcus neoformans.

Authors:  David van Duin; Wendy Cleare; Oscar Zaragoza; Arturo Casadevall; Joshua D Nosanchuk
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

10.  Factors Affecting Voriconazole Trough Concentration and Optimal Maintenance Voriconazole Dose in Chinese Children.

Authors:  Yi-Chang Zhao; Yang Zou; Jing-Jing Hou; Chen-Lin Xiao; Bi-Kui Zhang; Jia-Kai Li; Da-Xiong Xiang; Indy Sandaradura; Miao Yan
Journal:  Antibiotics (Basel)       Date:  2021-12-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.